We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Murky FDA Device Guidance Kills Sanofi Antitrust Suit

Law360, New York (January 11, 2018, 3:37 PM EST) -- Sanofi reasonably filed a patent for its insulin injector in the FDA's Orange Book, since the agency wasn't clear about whether it should, and rationally defended that patent against possible infringement, a Massachusetts federal magistrate judge said Wednesday when dismissing an antitrust suit over the conduct.

A proposed class of direct purchasers had claimed Sanofi-Aventis US LLC knew the patents didn’t belong in the U.S. Food and Drug Administration database and that the company then brought sham infringement litigation against Eli Lilly & Co. But U.S....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.